Publications

1.    Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL, (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology 83(7):952-61 [PMC3288656]

2.    Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. (2012). Cytochrome p450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos; 40(11):2174-84. [PMC3477201]

3.    Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2012).  “K2 Toxicity: Psychiatric Complications Following AM2201 Exposure,” Journal of Forensic Sciences, (in press).

4.    Seely K, Brents L, Radominska-Pandya A, Endres G, Keyes G, Moran JH, Prather PL. (2012).A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 25(4):825-7. [PMCID in progress]

5.    Seely KA, Lapoint J, Moran JH, Fattore L (2012).  Spice drugs are more than harmless herbal blends:  a review of the pharmacology and toxicology of synthetic cannabinoidsProgress in Neuro-Psychopharmacology & Biological Psychiatry.  E-Published before print.

6.    Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. (2011) Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. PLoS One, 6(7), e21917. [PMC 3130777]

7.    Chimalakonda KC, Bratton SM, Le V-H, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, Radominska-Pandya A (2011). Conjugation of Synthetic Cannabinoids, JWH-018 [Naphthalen-1-yl-(1-pentylindol-3-yl)methanone] and JWH-073 [naphthalen-1-yl-(1-butylindol-3-yl)methanone], Metabolites by Human UDP-glucuronosyltransferases Drug Metab Dispos 39(10):1967-76. [PMC3186213]

8.    Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH (2011). Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem.;83(16):6381-8. [PMC3155992]

9.  Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila), 49(8), 760-4. [PMC not assigned]

10.  Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH (2011). Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine. Anal Chem 83(11):4228-36. [PMC3105467]

11.  Moran JH (2011). Smart resource allocation needed to study “legal highsNat Med, 17(11), 1339.

12.  Seely KA, Prather PL, James LP, Moran JH. (2011) Marijuana-based drugs: Innovative therapeutics or designer drugs of abuse?  Mol Interv, 11(1), 36-51.

13.  Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC and Woods JH (2010) Interaction of 5-HT2A and 5-HT2C receptors in DOI-elicited head twitch behavior in mice. J Pharmacol Exp Ther 335(3):728-34. PMCID: PMC2993545

14.  Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH (2009). Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37(7):1496-504. [PMC2698943]